Overview

A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult Volunteers

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the single-dose pharmacokinetics (how the drug is absorbed in the body, distributed within the body, and how it is removed from the body) of the solution formulation to the tablet formulation; therefore the lowest dose available in the tablet formulation (250 mg) was selected.

Phase:

Phase 1

Details

Lead Sponsor:

Cougar Biotechnology, Inc.

Treatments:

Abiraterone Acetate